836 related articles for article (PubMed ID: 26298715)
1. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
; Kempen JH; Altaweel MM; Drye LT; Holbrook JT; Jabs DA; Sugar EA; Thorne JE
Ophthalmology; 2015 Oct; 122(10):1967-75. PubMed ID: 26298715
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial.
; Kempen JH; Altaweel MM; Holbrook JT; Jabs DA; Louis TA; Sugar EA; Thorne JE
Ophthalmology; 2011 Oct; 118(10):1916-26. PubMed ID: 21840602
[TBL] [Abstract][Full Text] [Related]
3. Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study.
Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group
Ophthalmology; 2015 Oct; 122(10):1976-86. PubMed ID: 26298718
[TBL] [Abstract][Full Text] [Related]
4. Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results.
Jaffe GJ; Lin P; Keenan RT; Ashton P; Skalak C; Stinnett SS
Ophthalmology; 2016 Sep; 123(9):1940-8. PubMed ID: 27421623
[TBL] [Abstract][Full Text] [Related]
5. Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.
; Kempen JH; Altaweel MM; Holbrook JT; Sugar EA; Thorne JE; Jabs DA
JAMA; 2017 May; 317(19):1993-2005. PubMed ID: 28477440
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Vision-Related Quality of Life for Patients with Noninfectious Uveitis Treated with Fluocinolone Acetonide Implant or Systemic Corticosteroid Therapy.
Sugar EA; Venugopal V; Thorne JE; Frick KD; Holland GN; Wang RC; Almanzor R; Jabs DA; Holbrook JT;
Ophthalmology; 2017 Nov; 124(11):1662-1669. PubMed ID: 28624167
[TBL] [Abstract][Full Text] [Related]
7. Effect of a Fluocinolone Acetonide Insert on Recurrence Rates in Noninfectious Intermediate, Posterior, or Panuveitis: Three-Year Results.
Jaffe GJ; Pavesio CE;
Ophthalmology; 2020 Oct; 127(10):1395-1404. PubMed ID: 32624244
[TBL] [Abstract][Full Text] [Related]
8. Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant.
Cai CX; Skalak C; Keenan RT; Grewal DS; Jaffe GJ
Graefes Arch Clin Exp Ophthalmol; 2020 May; 258(5):1023-1030. PubMed ID: 32114654
[TBL] [Abstract][Full Text] [Related]
9. Incidence and Outcome of Uveitic Glaucoma in Eyes With Intermediate, Posterior, or Panuveitis Followed up to 10 Years After Randomization to Fluocinolone Acetonide Implant or Systemic Therapy.
Kempen JH; Van Natta ML; Friedman DS; Altaweel MM; Ansari H; Dunn JP; Elner SG; Holbrook JT; Lim LL; Sugar EA; Jabs DA;
Am J Ophthalmol; 2020 Nov; 219():303-316. PubMed ID: 32628922
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis.
; Sugar EA; Holbrook JT; Kempen JH; Burke AE; Drye LT; Thorne JE; Louis TA; Jabs DA; Altaweel MM; Frick KD
Ophthalmology; 2014 Oct; 121(10):1855-62. PubMed ID: 24908205
[TBL] [Abstract][Full Text] [Related]
11. Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial.
Kempen JH; Van Natta ML; Altaweel MM; Dunn JP; Jabs DA; Lightman SL; Thorne JE; Holbrook JT;
Am J Ophthalmol; 2015 Dec; 160(6):1133-1141.e9. PubMed ID: 26386159
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.
Jaffe GJ; McCallum RM; Branchaud B; Skalak C; Butuner Z; Ashton P
Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758
[TBL] [Abstract][Full Text] [Related]
13. Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema.
Kempen JH; Sugar EA; Jaffe GJ; Acharya NR; Dunn JP; Elner SG; Lightman SL; Thorne JE; Vitale AT; Altaweel MM;
Ophthalmology; 2013 Sep; 120(9):1852-9. PubMed ID: 23706700
[TBL] [Abstract][Full Text] [Related]
14. Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results.
Tomkins-Netzer O; Lightman S; Drye L; Kempen J; Holland GN; Rao NA; Stawell RJ; Vitale A; Jabs DA;
Ophthalmology; 2015 Nov; 122(11):2351-9. PubMed ID: 26359188
[TBL] [Abstract][Full Text] [Related]
15. Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma.
Malone PE; Herndon LW; Muir KW; Jaffe GJ
Am J Ophthalmol; 2010 May; 149(5):800-6.e1. PubMed ID: 20189158
[TBL] [Abstract][Full Text] [Related]
16. Outcome of Treating Pediatric Uveitis With Dexamethasone Implants.
Tomkins-Netzer O; Talat L; Seguin-Greenstein S; Bar A; Lightman S
Am J Ophthalmol; 2016 Jan; 161():110-5.e1-2. PubMed ID: 26478217
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.
Suhler EB; Adán A; Brézin AP; Fortin E; Goto H; Jaffe GJ; Kaburaki T; Kramer M; Lim LL; Muccioli C; Nguyen QD; Van Calster J; Cimino L; Kron M; Song AP; Liu J; Pathai S; Camez A; Schlaen A; van Velthoven MEJ; Vitale AT; Zierhut M; Tari S; Dick AD
Ophthalmology; 2018 Jul; 125(7):1075-1087. PubMed ID: 29429764
[TBL] [Abstract][Full Text] [Related]
18. Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis.
Chieh JJ; Carlson AN; Jaffe GJ
Am J Ophthalmol; 2008 Oct; 146(4):589-594. PubMed ID: 18639220
[TBL] [Abstract][Full Text] [Related]
19. Postoperative outcomes after fluocinolone acetonide implant surgery in patients with birdshot chorioretinitis and other types of posterior and panuveitis.
Burkholder BM; Wang J; Dunn JP; Nguyen QD; Thorne JE
Retina; 2013 Sep; 33(8):1684-93. PubMed ID: 23549097
[TBL] [Abstract][Full Text] [Related]
20. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis.
Arcinue CA; Cerón OM; Foster CS
J Ocul Pharmacol Ther; 2013 Jun; 29(5):501-7. PubMed ID: 23297752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
